@article{
author = "Useini, Liridona and Mojić, Marija and Laube, Markus and Lönnecke, Peter and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Pietzsch, Jens and Hey‐Hawkins, Evamarie",
year = "2023",
abstract = "Fenoprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID) against rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and gout. Like other NSAIDs, fenoprofen inhibits the synthesis of prostaglandins by blocking both cyclooxygenase (COX) isoforms, COX-1 the “house-keeping” enzyme and COX-2 the induced isoform from pathological stimuli. Unselective inhibition of both COX isoforms results in many side effects, but off-target effects have also been reported. The steric modifications of the drugs could afford the desired COX-2 selectivity. Furthermore, NSAIDs have shown promising cytotoxic properties. The structural modification of fenoprofen using bulky dicarba-closo-dodecaborane(12) (carborane) clusters and the biological evaluation of the carborane analogues for COX inhibition and antitumor potential showed that the carborane analogues exhibit stronger antitumor potential compared to their respective aryl-based compounds.",
publisher = "John Wiley and Sons Ltd",
journal = "ChemMedChem",
title = "Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity",
number = "5",
volume = "18",
doi = "10.1002/cmdc.202200583",
pages = "e202200583"
}